 | |
| Clinical data | |
|---|---|
| Trade names | Pulmozyme |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694002 |
| Routes of administration | Inhalation |
| Legal status | |
| Legal status |
|
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 |
| Molar mass | 29253.9 g·mol−1 |
  (what is this?) (verify) | |
Dornase alfa, sold under the brand name Pulmozyme, is a medication used to treat cystic fibrosis.[1] It is used to decrease the thickness of mucus and thus make it easier to cough out.[1] It is used by breathing it in.[1]
Common side effects include change in voice, rash, throat inflammation, chest pain, runny nose, fever, and shortness of breath.[2] While there is no evidence of harm in pregnancy, such use has not been well studied.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which breaks up DNA outside the cell.[4]
Dornase alfa was approved for medical use in the United States in 1993.[1] In the United Kingdom a month of medication costs the NHS about £500 as of 2021.[4] In the United States this amount costs about 3,400 USD.[5]
References edit
- ^ a b c d "Dornase Alfa Monograph for Professionals". Drugs.com. Archived from the original on 11 August 2020. Retrieved 27 December 2021.
- ^ "DailyMed - PULMOZYME- dornase alfa solution". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 27 December 2021.
- ^ "Dornase alfa (Pulmozyme) Use During Pregnancy". Drugs.com. Archived from the original on 24 October 2020. Retrieved 27 December 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 309. ISBN 978-0857114105.
- ^ "Dornase Alfa Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.